- Home
- ABLV vs IPA Comparison
ABLV vs IPA Comparison
Compare ABLV & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- IPA
- Stock Information
- Founded
- ABLV 2015
- IPA 1983
- Country
- ABLV China
- IPA United States
- Employees
- ABLV N/A
- IPA N/A
- Industry
- ABLV
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- IPA Health Care
- Exchange
- ABLV Nasdaq
- IPA Nasdaq
- Market Cap
- ABLV 50.9M
- IPA 46.0M
- IPO Year
- ABLV N/A
- IPA 2017
- Fundamental
- Price
- ABLV $1.00
- IPA $1.20
- Analyst Decision
- ABLV
- IPA Strong Buy
- Analyst Count
- ABLV 0
- IPA 2
- Target Price
- ABLV N/A
- IPA $4.00
- AVG Volume (30 Days)
- ABLV 9.3K
- IPA 5.0M
- Earning Date
- ABLV 04-23-2025
- IPA 07-28-2025
- Dividend Yield
- ABLV N/A
- IPA N/A
- EPS Growth
- ABLV N/A
- IPA N/A
- EPS
- ABLV N/A
- IPA N/A
- Revenue
- ABLV $128,932,647.00
- IPA $16,581,105.00
- Revenue This Year
- ABLV N/A
- IPA $4.67
- Revenue Next Year
- ABLV N/A
- IPA $14.15
- P/E Ratio
- ABLV N/A
- IPA N/A
- Revenue Growth
- ABLV N/A
- IPA 1.34
- 52 Week Low
- ABLV $0.55
- IPA $0.27
- 52 Week High
- ABLV $1.90
- IPA $1.16
- Technical
- Relative Strength Index (RSI)
- ABLV 41.18
- IPA 75.91
- Support Level
- ABLV $1.02
- IPA $1.00
- Resistance Level
- ABLV $1.13
- IPA $1.15
- Average True Range (ATR)
- ABLV 0.07
- IPA 0.13
- MACD
- ABLV -0.01
- IPA 0.02
- Stochastic Oscillator
- ABLV 23.96
- IPA 94.38
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.